MedTrace Logo

Annexin A3 (ANXA3) as Protein-Based Marker for Non-Invasive Molecular Diagnostics of Prostate Carcinoma

NCT00400894 · Status: UNKNOWN · Type: OBSERVATIONAL · Enrollment: 750

Last updated 2007-02-05

No results posted yet for this study

Summary

Emerging from a differential proteomic study of sample pairs of prostate cancer and benign tissue, annexin A3 (ANXA3) was chosen as a potential novel biomarker for the early and non-invasive diagnosis of prostate cancer. We wanted to show or investigate, that:

* ANXA3 can be detected in urine after standard digital rectal examination.
* ANXA3 has better specificities than tPSA, in particular in the grey zone of PSA
* ANXA3 can help avoid unnecessary biopsies
* ANXA3 can in the long run replace PSA as a marker

Conditions

  • Prostate Cancer
  • Benign Prostatic Hyperplasia
  • Prostatic Intraepithelial Neoplasia

Sponsors & Collaborators

  • Charite University, Berlin, Germany

    collaborator OTHER

  • University Hospital Tuebingen

    collaborator OTHER

  • Medical Centre, Ludwigshafen, Germany

    collaborator UNKNOWN

  • Medical University Innsbruck

    collaborator OTHER

  • ProteoSys AG

    lead INDUSTRY

Principal Investigators

  • Martin Schostak, PD Dr. · University Medical Centre Charité, Berlin, Germany

  • André Schrattenholz, Prof. Dr. · ProteoSys AG, Mainz, Germany

Eligibility

Sex
MALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2005-09-30
Completion
2006-09-30

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00400894 on ClinicalTrials.gov